{"title":"在肺炎链球菌肺炎小鼠模型中评估头孢曲松方案的抗菌疗效:每天两次,每次 1 克与每天一次,每次 2 克。","authors":"Hideo Kato, Mao Hagihara, Shun-Ichi Hiramatsu, Hiroyuki Suematsu, Naoya Nishiyama, Nobuhiro Asai, Hiroshige Mikamo, Kazuko Yamamoto, Takuya Iwamoto","doi":"10.1093/jacamr/dlae092","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ceftriaxone is administered in regimens of either 2 g once-daily or 1 g twice-daily for the treatment of pneumonia caused by <i>Streptococcus pneumoniae</i>. Previous clinical study suggests the 2 g once-daily regimen is more effective, but comparison of antimicrobial efficacy between are lacking.</p><p><strong>Objectives: </strong>To assess the antimicrobial efficacy of these two ceftriaxone regimens against <i>S. pneumoniae</i> using a murine model of pneumonia.</p><p><strong>Methods: </strong>The study employed three <i>S. pneumoniae</i> isolates with ceftriaxone MICs of 1, 2 and 4 mg/L and two human-simulated regimens based on the blood concentration of ceftriaxone (1 g twice-daily and 2 g once-daily). Antimicrobial activity was quantified based on the change in bacterial counts (Δlog<sub>10</sub> cfu/lungs) observed in treated mice after 24 h, relative to the control mice at 0 h.</p><p><strong>Results: </strong>The human-simulated 2 g once-daily regimen of ceftriaxone exhibited significantly higher antimicrobial activity against <i>S. pneumoniae</i> isolates with MICs of 1 and 2 mg/L compared with the 1 g twice-daily regimen (1 mg/L, -5.14 ± 0.19 Δlog<sub>10</sub> cfu/lungs versus -3.47 ± 0.17 Δlog<sub>10</sub> cfu/lungs, <i>P</i> < 0.001; 2 mg/L, -3.41 ± 0.31 Δ log<sub>10</sub> cfu/lungs versus -2.71 ± 0.37 Δlog<sub>10</sub> cfu/lungs, <i>P</i> = 0.027). No significant difference in antimicrobial activity was observed against the <i>S. pneumoniae</i> isolate with a MIC of 4 mg/L between the two regimens (-0.33 ± 0.18 Δlog<sub>10</sub> cfu/lungs versus -0.42 ± 0.37 Δlog<sub>10</sub> cfu/lungs, <i>P</i> = 0.684).</p><p><strong>Conclusion: </strong>2 g once-daily regimen of ceftriaxone is more effective for treating pneumonia caused by <i>S. pneumoniae,</i> with MICs of ≤2 mg/L.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148390/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2 g once daily in a murine model of <i>Streptococcus pneumoniae</i> pneumonia.\",\"authors\":\"Hideo Kato, Mao Hagihara, Shun-Ichi Hiramatsu, Hiroyuki Suematsu, Naoya Nishiyama, Nobuhiro Asai, Hiroshige Mikamo, Kazuko Yamamoto, Takuya Iwamoto\",\"doi\":\"10.1093/jacamr/dlae092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ceftriaxone is administered in regimens of either 2 g once-daily or 1 g twice-daily for the treatment of pneumonia caused by <i>Streptococcus pneumoniae</i>. Previous clinical study suggests the 2 g once-daily regimen is more effective, but comparison of antimicrobial efficacy between are lacking.</p><p><strong>Objectives: </strong>To assess the antimicrobial efficacy of these two ceftriaxone regimens against <i>S. pneumoniae</i> using a murine model of pneumonia.</p><p><strong>Methods: </strong>The study employed three <i>S. pneumoniae</i> isolates with ceftriaxone MICs of 1, 2 and 4 mg/L and two human-simulated regimens based on the blood concentration of ceftriaxone (1 g twice-daily and 2 g once-daily). Antimicrobial activity was quantified based on the change in bacterial counts (Δlog<sub>10</sub> cfu/lungs) observed in treated mice after 24 h, relative to the control mice at 0 h.</p><p><strong>Results: </strong>The human-simulated 2 g once-daily regimen of ceftriaxone exhibited significantly higher antimicrobial activity against <i>S. pneumoniae</i> isolates with MICs of 1 and 2 mg/L compared with the 1 g twice-daily regimen (1 mg/L, -5.14 ± 0.19 Δlog<sub>10</sub> cfu/lungs versus -3.47 ± 0.17 Δlog<sub>10</sub> cfu/lungs, <i>P</i> < 0.001; 2 mg/L, -3.41 ± 0.31 Δ log<sub>10</sub> cfu/lungs versus -2.71 ± 0.37 Δlog<sub>10</sub> cfu/lungs, <i>P</i> = 0.027). No significant difference in antimicrobial activity was observed against the <i>S. pneumoniae</i> isolate with a MIC of 4 mg/L between the two regimens (-0.33 ± 0.18 Δlog<sub>10</sub> cfu/lungs versus -0.42 ± 0.37 Δlog<sub>10</sub> cfu/lungs, <i>P</i> = 0.684).</p><p><strong>Conclusion: </strong>2 g once-daily regimen of ceftriaxone is more effective for treating pneumonia caused by <i>S. pneumoniae,</i> with MICs of ≤2 mg/L.</p>\",\"PeriodicalId\":14594,\"journal\":{\"name\":\"JAC-Antimicrobial Resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148390/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAC-Antimicrobial Resistance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jacamr/dlae092\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2 g once daily in a murine model of Streptococcus pneumoniae pneumonia.
Background: Ceftriaxone is administered in regimens of either 2 g once-daily or 1 g twice-daily for the treatment of pneumonia caused by Streptococcus pneumoniae. Previous clinical study suggests the 2 g once-daily regimen is more effective, but comparison of antimicrobial efficacy between are lacking.
Objectives: To assess the antimicrobial efficacy of these two ceftriaxone regimens against S. pneumoniae using a murine model of pneumonia.
Methods: The study employed three S. pneumoniae isolates with ceftriaxone MICs of 1, 2 and 4 mg/L and two human-simulated regimens based on the blood concentration of ceftriaxone (1 g twice-daily and 2 g once-daily). Antimicrobial activity was quantified based on the change in bacterial counts (Δlog10 cfu/lungs) observed in treated mice after 24 h, relative to the control mice at 0 h.
Results: The human-simulated 2 g once-daily regimen of ceftriaxone exhibited significantly higher antimicrobial activity against S. pneumoniae isolates with MICs of 1 and 2 mg/L compared with the 1 g twice-daily regimen (1 mg/L, -5.14 ± 0.19 Δlog10 cfu/lungs versus -3.47 ± 0.17 Δlog10 cfu/lungs, P < 0.001; 2 mg/L, -3.41 ± 0.31 Δ log10 cfu/lungs versus -2.71 ± 0.37 Δlog10 cfu/lungs, P = 0.027). No significant difference in antimicrobial activity was observed against the S. pneumoniae isolate with a MIC of 4 mg/L between the two regimens (-0.33 ± 0.18 Δlog10 cfu/lungs versus -0.42 ± 0.37 Δlog10 cfu/lungs, P = 0.684).
Conclusion: 2 g once-daily regimen of ceftriaxone is more effective for treating pneumonia caused by S. pneumoniae, with MICs of ≤2 mg/L.